Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + fluorouracil
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A1811 + fluorouracil is a combination of two anticancer agents used in the treatment of advanced solid tumors, including colorectal cancer and HER2-mutant non-small cell lung cancer. SHR-A1811 is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor payload. It targets HER2-expressing or mutated tumor cells, delivering the cytotoxic payload directly to these cells to induce apoptosis through DNA damage by inhibiting topoisomerase I[4][6][8]. Fluorouracil is a small molecule antimetabolite that inhibits thymidylate synthase, thereby interfering with DNA synthesis and slowing or stopping the growth of rapidly dividing cancer cells[2]. The combination aims to enhance antitumor efficacy by leveraging both targeted delivery (via SHR-A1811) and broad cytotoxic activity (via fluorouracil). Clinical trials are ongoing for this combination in advanced solid tumors[3][7].
- Brand names
- None
- Other names
- 5-fluorouracil5-FU
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on SHR-A1811 + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + fluorouracil.